Holen Sie sich die Stockscreener-App
16.28
1.33%
-0.22
Vorhandelsmarkt:
14.45
-1.83
-11.24%
Schlusskurs vom Vortag:
$16.50
Offen:
$16.94
24-Stunden-Volumen:
50,928
Relative Volume:
1.59
Marktkapitalisierung:
$5.51B
Einnahmen:
$417.75M
Nettoeinkommen (Verlust:
$32.27M
KGV:
166.97
EPS:
0.0975
Netto-Cashflow:
-
1W Leistung:
+4.83%
1M Leistung:
-5.07%
6M Leistung:
-4.46%
1J Leistung:
+0.00%
1-Tages-Spanne:
$16.00
$16.94
1-Wochen-Bereich:
$15.50
$16.94
52-Wochen-Spanne:
$13.61
$30.36
Telix Pharmaceuticals Ltd Adr Stock (TLX) Company Profile
Firmenname
Telix Pharmaceuticals Ltd Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie TLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TLX
Telix Pharmaceuticals Ltd Adr
|
16.28 | 5.20B | 417.75M | 32.27M | 0 | 0.0975 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-06-05 | Eingeleitet | Wedbush | Outperform |
| 2024-11-15 | Eingeleitet | UBS | Buy |
Telix Pharmaceuticals Ltd Adr Aktie (TLX) Neueste Nachrichten
Telix Pharma slides 10% on SEC probe into cancer treatment - Investing.com
Telix Earnings Report: $204M Revenue Crushes Estimates as New Drug Launch Boosts Growth - Stock Titan
Medicare Grants Crucial Reimbursement Code for Telix's Next-Gen Prostate Cancer Imaging Agent - Stock Titan
FDA Approval: Illuccix Expansion Could Add 20,000 Annual Prostate Cancer Scans - Stock Titan
Revolutionary Dual-Isotope Cancer Imaging: Telix Unveils AlFluor Platform with Phase 3 Trial Success - Stock Titan
Revolutionary PSMA-PET Imaging Agent Gozellix Transforms Prostate Cancer Detection Across United States - Stock Titan
Leading Cancer Experts Reveal Future of Radiopharmaceuticals at Telix NYC Investor Day - Stock Titan
5 of the best ASX 200 shares to buy in June - The Motley Fool Australia
Telix Leaders Reveal Next-Gen Radiopharmaceutical Pipeline at Exclusive NYC Investor Day - Stock Titan
Radiopharmaceuticals Market Products and Applications Report 2025 | SPECT Radiopharmaceuticals Lead Diagnostic Market with 67% Share - GlobeNewswire Inc.
Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy - Stock Titan
Major Breakthrough: France Grants Approval for Advanced Prostate Cancer Detection Technology - Stock Titan
Telix Delivers Record $186M Q1 Revenue as New FDA-Approved Cancer Imaging Agent Bolsters Portfolio - Stock Titan
Breakthrough Brain Cancer Treatment Doubles Survival Time: Phase 2 Results Revealed - Stock Titan
Telix's Groundbreaking Prostate Cancer Imaging Tech Secures Nationwide Distribution Network - Stock Titan
Former ARTMS Tech Chief Joins Telix to Lead Next-Gen Radiopharmaceutical Innovation - Stock Titan
Major Board Addition: Ex-GSK and Sanofi Leader Joins Telix Pharmaceuticals - Stock Titan
Revolutionary Cancer Diagnostic Begins Human Trials: First Patient Receives Novel Sarcoma Imaging Agent - Stock Titan
FDA Green Lights Revolutionary Prostate Cancer Detection Tool: What Makes Gozellix a Game-Changer - StockTitan
Telix Pharmaceuticals Limited (ASX:TLX) Receives FDA Approval for Gozellix® - The Capital Club
Paladin Energy Ltd (ASX:PDN) Suspends Operations at Langer Heinrich Mine - The Capital Club
Major Breakthrough: First PSMA-PET Imaging Agent Approved in Brazil's $330M Market - StockTitan
Telix's Game-Changing Isotope Technology Revolutionizes Cancer Treatment Production - StockTitan
Can Telix's Cancer Therapies Transform Urology Treatment? Top Oncologists Weigh In - StockTitan
Could This New Kidney Cancer Imaging Tool Transform Diagnosis? FDA Fast-Tracks Review - StockTitan
Could This New Prostate Cancer Treatment Change Patient Outcomes? Miami Trial Now Recruiting - StockTitan
〈強茂展望〉擴大海外布局 越南廠最快2026年量產 - Yahoo 財經
Telix Pharmaceuticals Ltd (TLPPF) (FY 2024) Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada
Can Telix's Triple Product Launch in 2025 Justify Its Bold $1.2B Revenue Target? - StockTitan
特朗普：或將DOGE所節省開支的20%歸還予美國納稅人 - Yahoo 財經
港股美國預託證券與本港收市比較個別發展 - Yahoo 財經
據報匯控最快下周啟動投行部門新一輪裁員 由亞洲開始 - Yahoo 財經
Clinical Trial Success: Telix's Revolutionary Prostate Cancer Treatment Shows Promising Results - StockTitan
Major Breakthrough: Revolutionary Prostate Cancer Detection Tool Gets UK Green Light - StockTitan
分析國產人工智能 DeepSeek 的優與劣及其競爭力 - Yahoo 財經
Telix Pharmaceuticals acquires ImaginAb assets and technology - Investing.com
Telix Pharmaceuticals Acquires RLS USA in Major $230M Radiopharmacy Network Deal - Stock Titan
ImaginAb Sells Therapeutic Pipeline to Telix Pharmaceuticals, Focuses on CD8 ImmunoPET Development - Stock Titan
Telix Pharmaceuticals Secures European Approval for Breakthrough Prostate Cancer Imaging Agent Illuccix - Stock Titan
Telix Pharmaceuticals Hits Record $517M Revenue, Up 55% as Cancer Imaging Portfolio Expands - Stock Titan
Telix Pharmaceuticals Acquires ImaginAb's Cancer Drug Pipeline in $45M Strategic Deal - StockTitan
ASX December health sector winners… and a 91pc drop for a trial-flopped stock - Stockhead
勞力士據報因材料及勞動力成本上漲 加價最多8% - Yahoo 財經
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
無人機技術公司Red Cat(RCAT.US)股價漲18% 將與Palantir(PLTR.US)合作 - Yahoo 財經
Clayton Utz M&A partner Niro Ananda set to resign; KWM eyed - The Australian Financial Review
Health Check: ASX sleep company emerges from slumber with a revenue and earnings upgrade - Stockhead
〈熱門股〉正崴切入BBU 股價直奔漲停創4個月高 - Yahoo 財經
UBS bullish on Telix stock—Illuccix growth & therapeutic expansion fuel upside - Investing.com
Key Investors Say Bet on These Stocks at Sohn Australia Conference - BNN Bloomberg
TLXTelix Pharmaceuticals Ltd ADR Latest Stock News & Market Updates - Stock Titan
Finanzdaten der Telix Pharmaceuticals Ltd Adr-Aktie (TLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):